Cofactor Genomics is a biotechnology company specializing in RNA-based predictive diagnostics to enhance precision medicine, particularly in oncology. By analyzing RNA expression profiles, Cofactor develops diagnostic tools that predict patient responses to immunotherapies, aiming to improve treatment outcomes and reduce unnecessary interventions. Their flagship product, OncoPrism®, utilizes machine learning to assess tumor RNA, providing clinicians with actionable insights into immune engagement and therapy responsiveness. This approach addresses the limitations of traditional single-analyte biomarkers by offering a multidimensional perspective on tumor biology. Key Features and Functionality: - RNA-Based Immune Profiling: Cofactor's ImmunoPrism™ platform analyzes RNA from formalin-fixed paraffin-embedded (FFPE) tumor samples to quantify immune cell presence and activity, offering a comprehensive view of the tumor microenvironment. - Machine Learning Integration: The company employs advanced machine learning algorithms to interpret complex RNA data, identifying patterns that predict patient responses to immunotherapies. - Multidimensional Biomarkers: Moving beyond traditional single-analyte biomarkers, Cofactor develops multidimensional RNA biomarkers that provide a more accurate and nuanced understanding of tumor behavior and immune interactions. - Clinical Validation: Products like OncoPrism® have undergone rigorous clinical validation, demonstrating their efficacy in predicting immunotherapy responses across various solid tumor types. Primary Value and User Solutions: Cofactor Genomics addresses the critical challenge of matching cancer patients with the most effective immunotherapies. By providing predictive diagnostics based on RNA analysis, they enable clinicians to make informed treatment decisions, potentially increasing the success rates of immunotherapies and minimizing exposure to ineffective treatments. This personalized approach not only enhances patient outcomes but also contributes to more efficient and cost-effective healthcare delivery.